With today's submittal to FDA, the CEO stated the following:
"In discussions with potential partners, we believe we have seen the same commitment from them to transform the benefit/risk profile of aspirin that has driven our team at POZEN over the past several years. We look forward to completing a commercial deal in the upcoming months with a partner that shares our passion for this product, our values, and is capable of making PA reach its fullest potential in the marketplace."
This has a much more advanced time0table sound to it, for a partnership, than prior comments of the CEO.
About darn time they resubmitted after being ambushed by the FDA last time - any guesses to the partner? The big 3 are all losing big money making patents, assume they won't go with the AZN clowns again. Which BP is heavy into cardio drugs?